RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left"> NEW YORK, April 05, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong>WHY:</strong> Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RARE" rel="nofollow">RARE</a>) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important <strong>April 6, 2026 lead plaintiff deadline. </strong></p> <p align="justify"><strong>SO WHAT: </strong>If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p> <p align="justify"><strong>WHAT TO DO NEXT: </strong>To join the Ultragenyx class action, go to <a href="https://www.globenewswire.com/Tracker?data=Fw6m69F071Fe4oa_ezzdZSZT1ZgtOnvrunFAq_wtNiHEdIskRUH7hwdBy-Eyb1kBTmhNeks6UGl8QZ844zhlgQFHzNo_yaQdEkNLSPdAK78PqdeQ_EOhDLEqmCUkH7kYAfcPWte7w3skUVL1ki3RkMGOLUmAFDRmMmEGLH5u_1w=" rel="nofollow" target="_blank" rel="nofollow">https://rosenlegal.com/submit-form/?case_id=52472</a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email <a href="https://www.globenewswire.com/Tracker?data=1bjIKBJ7jhmLIS2qJQG987LvYdUzr4GLNIYJvREoQ86KlbJNnjINt53sxAe3Mt5-CjANZNxVAzifFDUvDeLLYIgLayOINETjxc1xBEV1Ny0=" rel="nofollow" target="_blank" rel="nofollow">[email protected]</a> for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court<strong> no later than April 6, 2026. </strong>A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p> <p align="justify"><strong>WHY ROSEN LAW: </strong>We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. <strong>Many of these firms do not actually litigate securities class actions, but are merely middlemen that ...</strong></p><p><a href=https://www.benzinga.com/pressreleases/26/04/g51651119/rare-deadline-notice-rosen-skilled-investor-counsel-encourages-ultragenyx-pharmaceutical-inc-inves?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel alt=RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE>Full story available on Benzinga.com</a></p>